Bellerophon Therapeutics BLPH

$ 0.1 -74.18%

Quarterly report 2023-Q3
added 11-14-2023

Bellerophon Therapeutics Balance Sheet 2011-2024 | BLPH

Annual Balance Sheet Bellerophon Therapeutics

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-23.8 M	-45.9 M	-7.56 M	-16.6 M	-28.8 M	-14.5 M	-6.26 M	-16.8 M	-	-	-
Long Term Debt	-	203 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	203 K	752 K	704 K	658 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	1.93 M	6.96 M	32.3 M	5.22 M	-	-	5.38 M	3.25 M	-
Total Current Liabilities	5.4 M	5.05 M	10.4 M	7.58 M	7.54 M	7.08 M	6.5 M	8.07 M	-	-	-	-
Total Liabilities	5.4 M	5.26 M	12 M	9.52 M	14.5 M	39.4 M	11.7 M	8.07 M	10.5 M	19.4 M	14.5 M	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-252 M	-232 M	-214 M	-190 M	-176 M	-179 M	-124 M	-101 M	-54.2 M	-177 M	-115 M	-
Total Assets	7.94 M	26.9 M	50.2 M	13.1 M	18.4 M	36.8 M	29.7 M	38.4 M	33.4 M	3.64 M	3.35 M	-
Cash and Cash Equivalents	6.92 M	24.7 M	47.6 M	9.87 M	16.6 M	28.8 M	14.5 M	6.26 M	16.8 M	-	-	-
Book Value	2.53 M	21.6 M	38.2 M	3.59 M	3.86 M	-2.59 M	18 M	30.3 M	22.9 M	-15.7 M	-11.1 M	-
Total Shareholders Equity	2.53 M	21.6 M	38.2 M	3.59 M	3.86 M	-2.59 M	18 M	30.3 M	22.9 M	-15.7 M	-	-

All numbers in USD currency

Quarterly Balance Sheet Bellerophon Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	8 K	203 K	396 K	586 K	773 K	956 K	956 K	956 K	956 K	1.66 M	1.66 M	1.66 M	1.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	1.26 M	5.62 M	5.36 M	5.4 M	5.18 M	5.45 M	5.58 M	5.26 M	5.52 M	6.98 M	9.06 M	12 M	12 M	12 M	12 M	9.52 M	9.52 M	9.52 M	9.52 M	14.5 M	14.5 M	14.5 M	14.5 M	39.4 M	39.4 M	39.4 M	39.4 M	11.7 M	11.7 M	11.7 M	11.7 M	8.07 M	8.07 M	8.07 M	8.07 M	10.5 M	10.5 M	10.5 M	10.5 M	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-256 M	-254 M	-249 M	-252 M	-247 M	-242 M	-238 M	-232 M	-228 M	-223 M	-220 M	-214 M	-214 M	-214 M	-214 M	-190 M	-190 M	-190 M	-190 M	-176 M	-176 M	-176 M	-176 M	-179 M	-179 M	-179 M	-179 M	-124 M	-124 M	-124 M	-124 M	-101 M	-101 M	-101 M	-101 M	-54.2 M	-54.2 M	-54.2 M	-54.2 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	4.98 M	11.2 M	16 M	7.94 M	12.6 M	17.7 M	21.7 M	26.9 M	31.3 M	37.1 M	42.2 M	50.2 M	50.2 M	50.2 M	50.2 M	13.1 M	13.1 M	13.1 M	13.1 M	18.4 M	18.4 M	18.4 M	18.4 M	36.8 M	36.8 M	36.8 M	36.8 M	29.7 M	29.7 M	29.7 M	29.7 M	38.4 M	38.4 M	38.4 M	38.4 M	33.4 M	33.4 M	33.4 M	33.4 M	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	4.38 M	10.6 M	15.2 M	6.92 M	11.3 M	16.3 M	20 M	24.7 M	28.7 M	34.3 M	39.7 M	47.6 M	47.6 M	47.6 M	47.6 M	9.87 M	9.87 M	9.87 M	9.87 M	16.6 M	16.6 M	16.6 M	16.6 M	28.8 M	28.8 M	28.8 M	28.8 M	14.2 M	14.5 M	14.5 M	14.5 M	6.26 M	6.26 M	6.26 M	6.26 M	16.8 M	16.8 M	16.8 M	16.8 M	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	3.72 M	5.62 M	10.6 M	2.53 M	7.43 M	12.3 M	16.2 M	21.6 M	25.8 M	30.1 M	33.1 M	38.2 M	38.2 M	38.2 M	38.2 M	3.59 M	3.59 M	3.59 M	3.59 M	3.86 M	3.86 M	3.86 M	3.86 M	-2.59 M	-2.59 M	-2.59 M	-2.59 M	18 M	18 M	18 M	18 M	30.3 M	30.3 M	30.3 M	30.3 M	22.9 M	22.9 M	22.9 M	22.9 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	3.72 M	5.62 M	10.6 M	2.53 M	7.43 M	12.3 M	16.2 M	21.6 M	25.8 M	30.1 M	33.1 M	38.2 M	38.2 M	38.2 M	38.2 M	3.59 M	3.59 M	3.59 M	3.59 M	3.86 M	3.86 M	3.86 M	3.86 M	-2.59 M	-2.59 M	-2.59 M	-2.59 M	18 M	18 M	18 M	18 M	30.3 M	30.3 M	30.3 M	30.3 M	22.9 M	22.9 M	22.9 M	22.9 M	-15.7 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency